Liver Metastases Help Predict Overall Survival in Metastatic Prostate Cancer Patients
June 3, 2012 -- A collaborative research team studied liver metastases in relation to overall survival in men with treatment-resistant metastatic prostate cancer (TRMPCa). Typically, patients with TRMPCa who have liver metastases have poor prognosis for survival.
The research team, including authors William Kevin Kelly, Susan Halabi, Michael Anthony Carducci, Daniel J. George, John Francis Mahoney, Walter Michael Stadler, Michael J. Morris, Philip W. Kantoff, J. P. Monk and Eric Jay Small, found that men without liver metastases lived 8.2 months longer compared to men whose cancer did metastasize, despite both groups having similar progression free survival and response to docetaxel based chemotherapy.
The study was multi-institutional and included 1,050 patients. Researchers assessed the prognostic significance of liver metastases in predicting overall survival and progression free survival, adjusting for stratification factors.
Fifty-nine of those patients had documented liver metastases. Patients with liver metastases had higher baseline alkaline phosphatase (ALK) and lactate dehydrogenase (ADH) levels compared to patients without liver metastases. The median overall survival time in patients with liver metastases was 14.4 compared to 22.6 months for patients without liver metastasis. The HR for treatment effect (docetaxel and prednisone with either bevacizumab or placebo) for liver metastases was not statistically significant for either group.